NSCLC therapeutics marketlung cancer marketOncology investors and drug developers alike are keeping a close eye on the , as non-small cell lung cancer (NSCLC) — responsible for roughly 85% of all lung cancer diagnoses — continues to shift from conventional chemotherapy toward biomarker-guided and immune-based treatment. This transformation is reshaping the at large and cementing NSCLC as one of oncology's most competitive therapeutic battlegrounds.

Tracking NSCLC Incidence Across the 7MM

NSCLC marketNSCLC incidenceNon-small cell lung cancer marketUnderstanding the starts with patient burden. in the US alone reached approximately 203,000 new cases in 2025, a figure expected to inch up to around 205,000 by 2036. Even as long-standing tobacco-control efforts gradually stabilize overall case counts, broader adoption of low-dose CT screening and incidental imaging discoveries are pushing more early-stage diagnoses to the surface. Disease burden also skews toward men and adults over 65, though a notable rise in younger patients is prompting renewed attention across the .

Lung Cancer Therapeutics Market Size and Forecast

Lung cancer therapeutics marketNSCLC market sizeThe , with NSCLC as its dominant driver, was valued at roughly USD 33 billion across the seven major markets (US, EU4, UK, Japan) in 2025. Forecasts point to nearly USD 67 billion by 2036, translating to a 6.6% CAGR over the decade. This trajectory reflects the 's dependence on an expanding wave of targeted agents, antibody-drug conjugates, and immunotherapy combinations replacing older systemic chemotherapy regimens as standard practice.

EGFR NSCLC Market: A Crowded, High-Value Segment

NSCLC treatment marketEGFR NSCLC marketWithin the , the stands out as one of the most lucrative biomarker-defined segments, generating close to USD 3.8 billion in the US in 2025 alone. AstraZeneca's TAGRISSO remains the entrenched leader here, though Johnson & Johnson's RYBREVANT — especially in combination with the oral TKI LAZCLUZE — is steadily chipping away at share. Exon 20 insertion mutations and rarer atypical EGFR alterations remain an active area of competition, with newer entrants like ZEGFROVY (sunvozertinib) demonstrating strong late-stage trial results against standard chemotherapy.

PD-1 NSCLC Market and the Immunotherapy Landscape

Non-small cell lung cancer marketPD-1 NSCLC marketNSCLC therapeutics marketNo discussion of the is complete without the , anchored firmly by Merck's KEYTRUDA, often described as the gold-standard first-line option when combined with platinum chemotherapy irrespective of PD-L1 status. OPDIVO, TECENTRIQ, and TEVIMBRA round out a competitive checkpoint-inhibitor field. Acquired resistance to anti-PD-1/L1 agents remains a persistent challenge, driving fresh interest in second-line combinations and novel mechanisms within the pipeline.

Beyond EGFR and PD-1: ALK, KRAS, and Emerging Targets

NSCLC marketlung cancer marketThe extends well past its two largest biomarker categories. ALK-positive disease generated close to USD 1.28 billion in the US in 2025, with ALECENSA holding the lead as preferred first-line therapy over ALUNBRIG. KRAS G12C, the most frequent KRAS variant in NSCLC, is becoming increasingly crowded as more approved and pipeline drugs target it. Rarer biomarkers — ROS1, HER2, RET fusions, and NTRK alterations — are also seeing meaningful pipeline progress, broadening the competitive scope of the .

Where the NSCLC Treatment Market Goes From Here

NSCLC treatment marketNSCLC market sizelung cancer therapeutics marketDespite this progress, the still grapples with real gaps: early-stage (Stage I–III) disease continues to rely on surgery and adjuvant chemotherapy with limited survival benefit, reimbursement hurdles persist across Europe, and combination-therapy costs remain high. Even so, with a deep pipeline of bispecific antibodies, antibody-drug conjugates, and next-generation TKIs advancing through clinical trials, the is set to nearly double by 2036 — reaffirming NSCLC's position at the center of the evolving .

Latest Reports Offered by Delveinsight

axial spondyloarthritis market bacteremia market basal cell carcinoma market basal cell nevus syndrome market benign prostatic hyperplasia market beta thalessemia market bile duct cancer market biliary stents market biliary tract cancers market biliary tract carcinoma market biochips market birch allergy market bronchial neoplasm market bronchiectasis market bullous keratopathy market bullous pemphigoid market bunion market burkitt lymphoma market burn pain market campylobacter infections market cancer pain market cardiac arrhythmia monitoring devices market cardiac implantable electronic devices market cardiogenic shock market cardiovascular monitoring and diagnostic devices market cataract surgery complications market | | | | | | | | | | | | | | | | | | | | | | | | | |

About Delveinsight

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Contact Us

Kanishk

kkumar@delveinsight.com

Global Non-Small Cell Lung Cancer Market: Market Dynamics, Trends, and Future Growth

Disease burden also skews toward men and adults over 65, though a notable rise in younger patients is prompting renewed attention